No Data
No Data
Asian Equities Traded in the US as American Depositary Receipts Open Week Slightly Lower in Tuesday Trading
Asian equities traded in the US as American depositary receipts opened the week modestly lower Tuesday morning, declining 0.19% to 1,947.18 on the S&P Asia 50 ADR Index. From North Asia, the gainers w
Dr. Reddy's Laboratories Announces The Appointment Of Milan Kalawadia To CEO North America >RDY
Dr. Reddy's Laboratories Announces The Appointment Of Milan Kalawadia To CEO North America >RDY
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower
Asian equities traded in the US as American depositary receipts were trending higher Friday morning, rising 1.01% to 1,951.87 on the S&P Asia 50 ADR Index. Despite the gain, the index is set to close
Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading
Asian equities traded in the US as American depositary receipts were modestly lower Wednesday morning, declining 0.25% to 1,947.30 on the S&P Asia 50 ADR Index. From North Asia, the gainers were led b
Alvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (Denosumab), a Biosimilar Candidate to Prolia & Xgeva in the U.S., Europe and UK
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ("Alvotech"), and Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's"), today announced that the companies have entered into a license and supply agreement for the commercialization of AVT03, Alvotech's biosimilar candidate to Prolia and Xgeva (denosumab).
Alvotech and Dr. Reddy's Collaborate for Commercialization of Denosumab
No Data